title: The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants.
abstract: Lupus anticoagulants (LA) are immunoglobulins (IgG, IgM, IgA or a mixture) which interfere with in vitro phospholipid (PL) dependent tests of coagulation (e.g. APTT, KCT, dilute Russell Viper Venom Time). LA are heterogeneous; consequently, the laboratory diagnosis is difficult and relies on multiple tests. We have developed a sensitive and relatively specific confirmatory test system based on fractions of two snake venoms. Textarin, a protein fraction of Pseudonaja textilis venom (Australian Eastern brown snake), activates prothrombin in the presence of PL, factor V and calcium ions. Ecarin, a protein fraction of Echis carinatus venom, will activate prothrombin in the absence of any cofactors. The activation of prothrombin by Textarin yields thrombin while Ecarin yields meizothrombin. In the presence of LA, the Textarin time is prolonged and the Ecarin time is unaffected. The test results are reported as a ratio of Textarin/Ecarin times (abnormal greater than 1.3). We have evaluated this test system in the following patient populations: LA positive, therapeutically heparinized, stable oral anticoagulated, liver disease, routine preoperative, anticardiolipin antibody positive LA negative, hemophilia A, various other hereditary factor deficiencies or dysfunctional proteins, and specific inhibitors of factor V and factor VIII. The LA positive patients represented a mixed population of autoimmune disease, drug-induced and post-infectious states. Our findings indicate the sensitivity of the Textarin/Ecarin system in the confirmation of LA. In order to use the test system most effectively, it is recommended to incorporate polybrene with Textarin when evaluating heparinized samples. Factor V deficiency and specific inhibitors of factor V yielded, in some instances, false positive results.
authors.affiliation: Department of Research, Ball Memorial Hospital, Muncie, Indiana 47303.
authors.forename: D A
authors.initials: DA
authors.lastname: Triplett
authors.forename: K F
authors.initials: KF
authors.lastname: Stocker
authors.forename: G A
authors.initials: GA
authors.lastname: Unger
authors.forename: L K
authors.initials: LK
authors.lastname: Barna
mesh_terms: D000284:Administration, Oral; D001777:Blood Coagulation / Q000187:drug effects*; D010450:Endopeptidases; D005343:Fibrinolytic Agents; D006493:Heparin / Q000627:therapeutic use; D006583:Hexadimethrine Bromide; D006801:Humans; D008107:Liver Diseases / Q000097:blood; D016682:Lupus Coagulation Inhibitor / Q000097:blood*; D011300:Preoperative Care; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012910:Snake Venoms
chemical_list: D005343:Fibrinolytic Agents; D016682:Lupus Coagulation Inhibitor; D012910:Snake Venoms; D006583:Hexadimethrine Bromide; D006493:Heparin; D010450:Endopeptidases; C020097:ecarin